ZyVersa Therapeutics (ZVSA) - Channelchek Takeaway Series - The J.P.Morgan Healthcare Conference

A brief corporate overview from ZyVersa Co-Founder, CEO, and Chairman Stephen Glover, followed by a Q&A with Noble Capital Markets Senior Research Analyst Robert LeBoyer.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. ZyVersa’s focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. The company’s development pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis (FSGS). Other potential indications for VAR 200 include Alport syndrome and diabetic kidney disease. ZyVersa’s development pipeline also includes a novel inflammasome ASC inhibitor, IC 100, to control damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

https://www.channelchek.com/company/zvsa

Скачать видео